Valuation Gilead Sciences, Inc. Berne S.E.

Stocks

End-of-day quote Berne S.E. 2026-02-10			5-day change	1st Jan Change
115.86 ^CHF	+69.18%		+57.76%	+69.18%

09-10	Gilead Sciences, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 10:55 AM
09-10	HSBC Adjusts Price Target on Gilead Sciences to $175 From $155, Keeps Buy Rating	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	91,081	107,677	100,942	115,118	152,281	179,558	-	-
Change	-	18.22%	-6.25%	14.04%	32.28%	17.91%	-	-
Enterprise Value (EV) ¹	118,530	126,522	118,665	131,838	169,585	196,303	188,682	182,392
Change	-	6.74%	-6.21%	11.1%	28.63%	15.75%	-3.88%	-3.33%
P/E	14.7x	23.6x	18x	243x	18.1x	-43.8x	18x	16.6x
PBR	4.32x	5.05x	4.48x	5.98x	6.73x	10.8x	7.96x	6.22x
PEG	-	-0.9x	0.8x	-2.7x	0x	0x	-0x	1.95x
Capitalization / Revenue	3.34x	3.95x	3.72x	4x	5.17x	5.85x	5.49x	5.23x
EV / Revenue	4.34x	4.64x	4.38x	4.59x	5.76x	6.4x	5.77x	5.31x
EV / EBITDA	8.12x	8.86x	9.01x	11.7x	10.6x	25x	10.6x	9.95x
EV / EBIT	9.45x	10.4x	11.3x	15.5x	12.9x	60.4x	11.9x	10.8x
EV / FCF	11x	15.2x	16x	12.8x	17.9x	-372x	14.4x	13.2x
FCF Yield	9.12%	6.59%	6.25%	7.82%	5.58%	-0.27%	6.93%	7.6%
Dividend per Share ²	2.84	2.92	3	3.08	3.16	3.291	3.349	3.012
Rate of return	3.91%	3.4%	3.7%	3.33%	2.57%	2.27%	2.31%	2.08%
EPS ²	4.93	3.64	4.5	0.38	6.78	-3.306	8.024	8.707
Distribution rate	57.6%	80.2%	66.7%	811%	46.6%	-99.5%	41.7%	34.6%
Net sales ¹	27,305	27,281	27,116	28,754	29,443	30,690	32,682	34,347
EBITDA ¹	14,598	14,283	13,177	11,287	15,953	7,859	17,834	18,324
EBIT ¹	12,548	12,180	10,484	8,520	13,193	3,248	15,834	16,889
Net income ¹	6,225	4,592	5,665	480	8,510	-4,275	10,275	10,917
Net Debt ¹	27,449	18,845	17,723	16,720	17,304	16,745	9,125	2,835
Reference price ²	72.61	85.85	81.01	92.37	122.74	144.81	144.81	144.81
Nbr of stocks (in thousands)	1,254,384	1,254,244	1,246,042	1,246,266	1,240,680	1,239,955	-	-
Announcement Date	2/1/22	2/2/23	2/6/24	2/11/25	2/10/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
ELI LILLY AND COMPANY	31.96x	11.62x	23.56x	0.62%	1,001B
JOHNSON & JOHNSON	29.63x	-	-	2.02%	642B
ABBVIE INC.	32.65x	7.56x	15.72x	2.69%	451B
ROCHE HOLDING AG	18.78x	4.58x	11.35x	2.9%	340B
NOVARTIS AG	19.52x	5.11x	12.66x	3.19%	263B
ASTRAZENECA PLC	20.44x	4.2x	12.01x	2.1%	247B
AMGEN INC.	24.19x	6.38x	11.35x	2.64%	207B
NOVO NORDISK A/S	12.74x	4.63x	9.67x	3.94%	197B
GILEAD SCIENCES, INC.	-43.8x	6.4x	24.98x	2.27%	180B
Average	16.23x	6.31x	15.16x	2.48%	391.82B
Weighted average by Cap.	23.23x	7.75x	17.18x	2.04%